Farms.com Home   Farm Equipment News

Art's Way Improves Profitability Despite Ongoing Ag Market Headwinds

ARMSTRONG, Iowa — Art's Way Manufacturing Co. Inc., a diversified manufacturer and distributor of equipment serving agricultural and research needs, announces its financial results for the second quarter of fiscal 2025.

President, CEO and Chairman Marc McConnell reports, "We are pleased to show operational progress and improved profitability during our second quarter despite challenging market conditions in the ag equipment space. During the quarter, we benefited greatly from sustained performance from our Modular Buildings segment while our Agricultural Products segment continued to see modest demand. We remain focused on enhancing our products and customer experience while also further improving our balance sheet and cashflow positions. We are pleased with our progress on these fronts and believe we are on firm footing to work through the uncertainty of the current environment with cautious optimism."

Consolidated -– Continuing Operations

  • Sales of $6,337,000 for Q2 2025, 5.8% decline from Q1 2024. Six-month sales of $11,478,000, 7.8% decline from the first six months of fiscal 2024.

  • Six-month gross profit improvement of 3.8% compared to the first six months of fiscal 2024.

  • Operating expenses reduced by 15.3% for the six months ending May 31, 2025 compared to the same period in fiscal 2024.

  • Net income of $1,426,000 for the six months ending May 31, 2025, $1,855,000 improvement from same period in fiscal 2024. We received an Employee Retention Credit refund during the six months ending May 31, 2025 that positively impacted net income by $1,154,000.

Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.